KR890014534A - 혈당 감소제로서 티아졸리딘디온 유도체 - Google Patents

혈당 감소제로서 티아졸리딘디온 유도체 Download PDF

Info

Publication number
KR890014534A
KR890014534A KR1019890002788A KR890002788A KR890014534A KR 890014534 A KR890014534 A KR 890014534A KR 1019890002788 A KR1019890002788 A KR 1019890002788A KR 890002788 A KR890002788 A KR 890002788A KR 890014534 A KR890014534 A KR 890014534A
Authority
KR
South Korea
Prior art keywords
compound
group
alkyl
oxazol
bond
Prior art date
Application number
KR1019890002788A
Other languages
English (en)
Other versions
KR910000734B1 (ko
Inventor
앨런 클라크 데이비드
웨인 골드스타인 스티븐
헐린 버나드
Original Assignee
윌리암 데이비스 헌
화이자 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 윌리암 데이비스 헌, 화이자 인크. filed Critical 윌리암 데이비스 헌
Publication of KR890014534A publication Critical patent/KR890014534A/ko
Application granted granted Critical
Publication of KR910000734B1 publication Critical patent/KR910000734B1/ko

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/44—Two oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Abstract

내용 없음.

Description

혈당 감소제로서 티아졸리딘디온 유도체
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음

Claims (8)

  1. 하기 구조식(I)의 화합물, 또는 이 화합물이 염기성 질소를 포함한 경우 그의 제약상 허용되는 산 부가염.
    상기식중, 점선은 결합이거나 결합이 아니고, V는 - CH=CH-, -N=CH, -CH=N-, S, O 또는 NR이고, W는 S, SO, SO2, SO2NR1, NR1SO2, CONR1또는 NR1CO이고, X는 S, O, NR2, -CH=N- 또는 -N=CH-이고, Y는 CH 또는 N이고, Z는 수소, (C1-C7)알킬, (C3-C7)시클로알킬, 페닐, 피리딜, 푸릴, 티에닐, 또는 페닐(이 기는 (C1-C3)알킬, 트리플루오로메틸, (C1-C3)알콕시, 플루오로, 클로로 또는 브로모인 동일하거나 상기한 기에 의해 일치환 또는 이치환됨)이고, Z1은 수소 또는 (C1-C3)알킬이고, R, R1및 R2은 각각 독립적으로 수소 또는 (C1-C4)알킬이고, n은 1,2 또는 3임.
  2. 제1항에 있어서, 점선이 결합이 아니고, V가 -CH=CH-이고, n이 1 또는 2인 화합물.
  3. 제2항에 있어서, n이 1이고, W가 CONR1이고, X가 0이고, Y가 옥사졸-4-일기를 형성하는 N인 화합물.
  4. 제2항에 있어서, n이 1이고, W가 NR1CO이고, X가 0이고, Y가 옥사졸-4-일기를 형성하는 N인 화합물.
  5. 제2항에 있어서, n이 2이고, W가 S 또는 SO2이고, X가 0이고, Y가 옥사졸-4-일기를 형성하는 N인 화합물.
  6. 제3항, 제4항 또는 제5항에 있어서, Z가 2-페닐기이고, Z1이 5-메틸기인 화합물.
  7. 제1항의 화합물 혈당 감소량 및 제약상 허용되는 담체로 되는, 과혈당증 포유 동물에서 사용하기 위한 제약 조성물.
  8. 제1항의 화합물 혈중 콜레스테롤 감소량 및 제약상 허용되는 담체로 되는, 과콜레스테롤혈증 포유 동물에서 사용하기 위한 제약 조성물.
    ※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
KR1019890002788A 1988-03-08 1989-03-07 혈당 감소제로서 티아졸리딘디온 유도체 KR910000734B1 (ko)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
USPCT/US88/00745 1988-03-08
PCT/US1988/000745 WO1989008652A1 (en) 1988-03-08 1988-03-08 Thiazolidinedione derivatives as hypoglycemic agents
US8800745 1988-03-08

Publications (2)

Publication Number Publication Date
KR890014534A true KR890014534A (ko) 1989-10-24
KR910000734B1 KR910000734B1 (ko) 1991-02-06

Family

ID=22208591

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019890002788A KR910000734B1 (ko) 1988-03-08 1989-03-07 혈당 감소제로서 티아졸리딘디온 유도체

Country Status (17)

Country Link
EP (1) EP0389699B1 (ko)
JP (1) JPH01299289A (ko)
KR (1) KR910000734B1 (ko)
CN (1) CN1026234C (ko)
AU (1) AU594899B2 (ko)
CA (1) CA1328265C (ko)
DK (1) DK108789A (ko)
ES (3) ES2052906T3 (ko)
FI (1) FI92696C (ko)
HU (1) HU217432B (ko)
IL (1) IL89481A (ko)
MY (1) MY103837A (ko)
NO (1) NO178068C (ko)
NZ (1) NZ228247A (ko)
PT (1) PT89922B (ko)
WO (1) WO1989008652A1 (ko)
ZA (1) ZA891681B (ko)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008651A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Hypoglycemic thiazolidinedione derivatives
GB8919417D0 (en) * 1989-08-25 1989-10-11 Beecham Group Plc Novel compounds
US5089514A (en) * 1990-06-14 1992-02-18 Pfizer Inc. 3-coxazolyl [phenyl, chromanyl or benzofuranyl]-2-hydroxypropionic acid derivatives and analogs as hypoglycemic agents
AU645112B2 (en) * 1990-08-23 1994-01-06 Pfizer Inc. Hypoglycemic hydroxyurea derivatives
FR2696743B1 (fr) * 1992-10-12 1994-12-23 Adir Nouveaux composés de thiazolidine dione, leur procédé de préparation et les compositions pharmaceutiques les contenant.
DE4317320A1 (de) * 1993-05-25 1994-12-01 Boehringer Mannheim Gmbh Neue Thiazolidindione und diese enthaltende Arzneimittel
JPH08157473A (ja) * 1994-10-06 1996-06-18 Nissan Chem Ind Ltd ピラゾール系チアゾリジン類
US5641796A (en) * 1994-11-01 1997-06-24 Eli Lilly And Company Oral hypoglycemic agents
JP3906935B2 (ja) * 1995-12-18 2007-04-18 杏林製薬株式会社 Ｎ−置換ジオキソチアゾリジルベンズアミド誘導体及びその製造法
AU2231397A (en) * 1996-03-08 1997-09-22 Torii Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives
DE19711616A1 (de) 1997-03-20 1998-09-24 Boehringer Mannheim Gmbh Verbessertes Verfahren zur Herstellung von Thiazolidindionen
US6355672B1 (en) * 1998-08-07 2002-03-12 Takeda Chemical Industries, Ltd. Benzothiepin derivatives, process for the preparation of the same and uses thereof
AU6023300A (en) * 1999-07-26 2001-02-13 Shionogi & Co., Ltd. Drug compositions exhibiting thrombopoietin agonism
JP4316787B2 (ja) * 2000-01-11 2009-08-19 壽製薬株式会社 エーテル又はアミド誘導体、その製法並びにそれを含有する糖尿病治療剤、
DE10029077A1 (de) 2000-06-13 2001-12-20 Bayer Ag Thiazolylsubstituierte Heterocyclen
CA2435143A1 (en) * 2001-01-26 2002-08-01 Shionogi & Co., Ltd. Halogen compounds having thrombopoietin receptor agonism
US20040077697A1 (en) * 2001-02-02 2004-04-22 Hiroyuki Koshio 2-Acylaminothiazole derivative or its salt
DE10331675A1 (de) 2003-07-14 2005-02-10 Bayer Cropscience Ag Hetarylsubstituierte Pyrazolidindion-Derivate
WO2008051197A2 (en) 2005-09-20 2008-05-02 Mayo Foundation For Medical Education And Research Small-molecule botulinum toxin inhibitors
GB2465890A (en) * 2008-12-05 2010-06-09 Scynexis Inc 2-Arylazole derivatives as antiprotozoal agents

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1003445B (zh) * 1984-10-03 1989-03-01 武田药品工业株式会社 噻唑烷二酮衍生物，其制备方法和用途
HU210339B (en) * 1985-05-21 1995-03-28 Pfizer Process for preparing thiazolidinediones and their pharmaceutical compositions haring hypoglycemic effect
JPH06779B2 (ja) * 1985-06-10 1994-01-05 武田薬品工業株式会社 チアゾリジオン誘導体およびそれを含んでなる医薬組成物

Also Published As

Publication number Publication date
CN1026234C (zh) 1994-10-19
ES2052906T3 (es) 1994-07-16
ES2052907T3 (es) 1994-07-16
HU882181D0 (en) 1991-01-28
MY103837A (en) 1993-09-30
NO903863L (no) 1990-09-05
IL89481A0 (en) 1989-09-10
KR910000734B1 (ko) 1991-02-06
CN1036572A (zh) 1989-10-25
EP0389699B1 (en) 1994-05-11
WO1989008652A1 (en) 1989-09-21
AU3107789A (en) 1989-09-14
DK108789D0 (da) 1989-03-07
JPH0585551B2 (ko) 1993-12-07
HU217432B (hu) 2000-01-28
NO178068C (no) 1996-01-17
JPH01299289A (ja) 1989-12-04
NO903863D0 (no) 1990-09-05
FI904413A0 (fi) 1990-09-07
NZ228247A (en) 1990-05-28
ZA891681B (en) 1990-10-31
FI92696B (fi) 1994-09-15
PT89922B (pt) 1995-03-01
IL89481A (en) 1993-02-21
DK108789A (da) 1989-09-09
EP0389699A1 (en) 1990-10-03
NO178068B (no) 1995-10-09
ES2052910T3 (es) 1994-07-16
FI92696C (fi) 1994-12-27
PT89922A (pt) 1989-11-10
AU594899B2 (en) 1990-03-15
CA1328265C (en) 1994-04-05
HUT54680A (en) 1991-03-28

Similar Documents

Publication Publication Date Title
KR890014534A (ko) 혈당 감소제로서 티아졸리딘디온 유도체
KR890014533A (ko) 혈당 감소제 티아졸리딘디온 유도체
KR950704269A (ko) 당뇨병 치료제
KR900018098A (ko) 피리돈 카르복실산과 항균제
KR960704884A (ko) 항종양제 또는 항바이러스제로서의 디스타마이신 A 동족체 (Distamycin A analogues as antitumour or antiviral agents)
KR870011129A (ko) 디스타마이신 a 동족체 및 이의 제조방법
KR900003151A (ko) 화합물
GB1520963A (en) Erythromycin derivatives
KR920021547A (ko) 아졸 유도체
KR890000477A (ko) 신규 화합물들
FR2403333A1 (fr) Analogues de la prostaglandine e1 et compositions pharmaceutiques les contenant
KR880000413A (ko) 항알레르기 및 소염 제제와 그의 제조방법
KR890014480A (ko) 2-피리딜아세트산 유도체, 이의 제조방법 및 이를 함유하는 약제학적 조성물
KR860700251A (ko) 신규한 삼환성 또는 사환성 화합물 및 그 염류의 제조방법
KR900018113A (ko) 티에노-트리아졸로-디아제핀 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR880011154A (ko) 벤즈옥사진 유도체 및 이의 제조방법
KR900014397A (ko) 티에노-트리아졸로-디아제핀 술포닐 유도체, 그의 제조 방법 및 그를 함유하는 치료 조성물
KR890009888A (ko) 헤테로시클릭 옥소프탈라지닐 아세트산
KR850001200A (ko) 아졸계 디옥솔란 유도체의 제조방법
KR900012925A (ko) 인돌 유도체
KR910016734A (ko) 광학활성 알킬렌디옥시벤젠 유도체 및 치료에의 용도
KR900018054A (ko) 헤테로사이클릭구아니딘 5ht₃길항물질
IT1206130B (it) Composti per abbassare i livelli dei lipidi.
KR890012990A (ko) 삼치환된 아민 이들의 제법 및 이들을 함유하는 제약조성물
KR880013929A (ko) 신규 5-메톡시 알킬 암노늄 테트라히드로푸란 및 테트라히드로티오펜

Legal Events

Date Code Title Description
A201 Request for examination
G160 Decision to publish patent application
E701 Decision to grant or registration of patent right
GRNT Written decision to grant
FPAY Annual fee payment

Payment date: 20030103

Year of fee payment: 13

LAPS Lapse due to unpaid annual fee